In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerance with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported...
- Neuroblastoma is the most common cancer in infants less than one year old and the third-most common pediatric cancer in children less than 15 years old, accounting for 15 percent of childhood cancer deaths...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso...
Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over yearTyvaso DPI™ NDA under review with FDA action expected in October 2021
SILVER SPRING, Md...
03 Aug 2021
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2021 financial results before the...
Forced vital capacity improvement observed during the INCREASE study in patients with idiopathic pulmonary fibrosis represents the basis of the TETON registration study of Tyvaso in IPF
SILVER SPRING, Md. and RESEARCH...
16 Jun 2021
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
FDA action expected in October 2021
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 16, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S...
07 Jun 2021
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 7, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation...
First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 3, 2021 /PRNewswire/ -- United Therapeutics Corporation...
25 May 2021
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 25, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...
Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD)Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug AdministrationTETON...